Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats

Pharmacology Biochemistry and Behavior

Volumn 94, Issue 2, 2009, Pages 244-249

  Morani, Aashish S ^a   Kivell, Bronwyn ^a   Prisinzano, Thomas E ^b   Schenk, Susan ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Cocaine self administration; Drug seeking; Kappa opioid agonist; Salvinorin A; Spiradoline; U50488H; U69593

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; COCAINE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; SALVINORIN A; SPIRADOLINE; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; HYPERACTIVITY; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; BEHAVIOR, ADDICTIVE; BENZENEACETAMIDES; COCAINE; DITERPENES, CLERODANE; MALE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SELF ADMINISTRATION;

RATTUS; SALVIA DIVINORUM;

EID: 72149090907     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.09.002     Document Type: Article

References (59)

1. Alleweireldt A., Weber S.M., Kirschner K.F., Bullock B.L., and Neisewander J.L. Blockade or stimulation of D1 dopamine receptors attenuates cue reinstatement of extinguished cocaine-seeking behavior in rats. Psychopharmacology (Berl) 159 3 (2002) 284-293
2. Baker L., Panos J., Killinger B., Peet M., Bell L., Haliw L., et al. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69593 and U50488 in rats. Psychopharmacology (Berl) 203 3 (2009) 203-211
3. Beardsley P.M., Howard J.L., Shelton K.L., and Carroll F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 183 1 (2005) 118-126
4. Braida D., Limonta V., Capurro V., Fadda P., Rubino T., Mascia P., et al. Involvement of kappa-opioid and endocannabinoid system on salvinorin A-induced reward. Biol Psychiatry 63 3 (2008) 286-292
5. Butelman E.R., Harris T., and Kreek M.J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 172 2 (2004) 220-224
6. Butelman E.R., Prisinzano T.E., Deng H., Rus S., and Kreek M.J. Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in non-human primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328 2 (2009) 588-597
7. Carlezon W.J., Beguin C., Dinieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316 1 (2006) 440-447
8. Chartoff E.H., Potter D., Damez-Werno D., Cohen B.M., and Carlezon Jr. W.A. Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 33 11 (2008) 2676-2687
9. Chavkin C., Sud S., Jin W., Stewart J., Zjawiony J.K., Siebert D.J., et al. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308 3 (2004) 1197-1203
10. Devine D.P., Leone P., Pocock D., and Wise R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther 266 3 (1993) 1236-1246
11. Fantegrossi W., Kugle K.M., Valdes III L.J., Koreeda M., and Woods J.H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 16 8 (2005) 627-633
12. Fischman M.W., Schuster C.R., Javaid J., Hatano Y., and Davis J. Acute tolerance development to the cardiovascular and subjective effects of cocaine. J Pharmacol Exp Ther 235 3 (1985) 677-682
13. Gehrke B.J., Chefer V.I., and Shippenberg T.S. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (Berl) 197 3 (2008) 509-517
14. Glick S.D., Maisonneuve I.M., Raucci J., and Archer S. Kappa-opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681 1-2 (1995) 147-152
15. Gray A.M., Rawls S.M., Shippenberg T.S., and McGinty J.F. The kappa-opioid agonist, U69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem 73 3 (1999) 1066-1074
16. Hahn B., Stolerman I.P., and Shoaib M. Kappa-opioid receptor modulation of nicotine-induced behaviour. Neuropharmacology 39 13 (2000) 2848-2855
17. Heidbreder C.A., and Shippenberg T.S. U69593 prevents cocaine sensitization by normalizing basal accumbens dopamine. NeuroReport 5 14 (1994) 1797-1800
18. Heidbreder C.A., Goldberg S.R., and Shippenberg T.S. The kappa-opioid receptor agonist U69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res 616 1-2 (1993) 335-338
19. Heidbreder C.A., Babovic-Vuksanovic D., Shoaib M., and Shippenberg T.S. Development of behavioral sensitization to cocaine: influence of kappa-opioid receptor agonists. J Pharmacol Exp Ther 275 1 (1995) 150-163
20. Heidbreder C.A., Thompson A.C., and Shippenberg T.S. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther 278 2 (1996) 490-502
21. Holtzman S.G. Further characterization of the discriminative stimulus effects of spiradoline. Pharmacol Biochem Behav 66 3 (2000) 517-522
22. Holtzman S.G., Cook L., and Steinfels G.F. Discriminative stimulus effects of spiradoline, a kappa-opioid agonist. Psychopharmacology (Berl) 105 4 (1991) 447-452
23. Jaffe J.H., Cascella N.G., Kumor K.M., and Sherer M.A. Cocaine-induced cocaine craving. Psychopharmacology (Berl) 97 1 (1989) 59-64
24. John T.F., French L.G., and Erlichman J.S. The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol 545 2-3 (2006) 129-133
25. Khroyan T.V., Barrett-Larimore R.L., Rowlett J.K., and Spealman R.D. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther 294 2 (2000) 680-687
26. Khroyan T.V., Platt D.M., Rowlett J.K., and Spealman R.D. Attenuation of relapse to cocaine seeking by dopamine D1 receptor agonists and antagonists in non-human primates. Psychopharmacology (Berl) 168 1-2 (2003) 124-131
27. Kreibich A.S., and Blendy J.A. cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement. J Neurosci 24 30 (2004) 6686-6692
28. Maisonneuve I.M., Archer S., and Glick S.D. U50488, a kappa-opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181 1-2 (1994) 57-60
29. McCurdy C.R., Sufka K.J., Smith G.H., Warnick J.E., and Nieto M.J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83 1 (2006) 109-113
30. McLaughlin J.P., Marton-Popovici M., and Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23 13 (2003) 5674-5683
31. McLaughlin J.P., Li S., Valdez J., Chavkin T.A., and Chavkin C. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 31 6 (2006) 1241-1248
32. Mello N.K., and Negus S.S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14 6 (1996) 375-424
33. Mello N.K., and Negus S.S. Effects of kappa-opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286 2 (1998) 812-824
34. Negus S.S., Mello N.K., Portoghese P.S., and Lin C.E. Effects of kappa-opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282 1 (1997) 44-55
35. Prisinzano T.E. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78 5 (2005) 527-531
36. Prisinzano T.E., and Rothman R.B. Salvinorin A analogues as probes in opioid pharmacology. Chem Rev 108 5 (2008) 1732-1743
37. Prisinzano T.E., Tidgewell K., and Harding W.W. Kappa-opioids as potential treatments for stimulant dependance. AAPS J 7 3 (2005) E592-E599
38. Redila V.A., and Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berl) 200 1 (2008) 59-70
39. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa-opioid selective agonist. Proc Natl Acad Sci U S A 99 18 (2002) 11934-11939
40. Schenk S., and Partridge B. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology (Berl) 147 3 (1999) 285-290
41. Schenk S., and Partridge B. Effect of the kappa-opioid receptor agonist, U69593, on reinstatement of extinguished amphetamine self-administration behavior. Pharmacol Biochem Behav 68 4 (2001) 629-634
42. Schenk S., Partridge B., and Shippenberg T.S. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144 4 (1999) 339-346
43. Schenk S., Partridge B., and Shippenberg T.S. Reinstatement of extinguished drug-taking behaviour in rats: effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl) 151 1 (2000) 85-90
44. Schmidt M.D., Schmidt M.S., Butelman E.R., Harding W.W., Tidgewell K., Murry D.J., et al. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in non-human primates. Synapse 58 3 (2005) 208-210
45. Self D.W., Barnhart W.J., Lehman D.A., and Nestler E.J. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271 5255 (1996) 1586-1589
46. Shippenberg T.S., Spanagel R., and Heidbreder C.A. Modulation of mesolimbic dopamine release by endogeneous opioids; role in drug-induced sensitization and dependance. In: Louilot A., Durkin T., Spampinato U., and Cardor M. (Eds). Monitoring molecules in neuroscience. Proc. 6th international conference on in vivo methods (1994) 123-125
47. Shippenberg T.S., LeFevour A., and Heidbreder C.A. Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276 2 (1996) 545-554
48. Shippenberg T.S., Zapata A., and Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116 2 (2007) 306-321
49. Siebert D.J. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43 1 (1994) 53-56
50. Thompson A.C., Zapata A., Justice Jr. J.B., Vaughan R.A., Sharpe L.G., and Shippenberg T.S. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20 24 (2000) 9333-9340
51. Tomasiewicz H.C., Todtenkopf M.S., Chartoff E.H., Cohen B.M., and Carlezon Jr. W.A. The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64 11 (2008) 982-988
52. Valdes III L.J. Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A. J Psychoact Drugs 26 3 (1994) 277-283
53. Valdés III L.J., Díaz J., and Paul A.G. Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling AND Játiva-M.). J Ethnopharmacol 7 3 (1983) 287-312
54. Willmore-Fordham C.B., Krall D.M., McCurdy C.R., and Kinder D.H. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats. Neuropharmacology 53 4 (2007) 481-486
55. Wit H., and Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (Berl) 75 2 (1981) 134-143
56. Worley C.M., Valadez A., and Schenk S. Reinstatement of extinguished cocaine-taking behavior by cocaine and caffeine. Pharmacol Biochem Behav 48 1 (1994) 217-221
57. Xi Z.-X., Fuller S.A., and Stein E.A. Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study. J Pharmacol Exp Ther 284 1 (1998) 151-161
58. Yan F., and Roth B.L. Salvinorin A: a novel and highly selective kappa-opioid receptor agonist. Life Sci 75 22 (2004) 2615-2619
59. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., and Kreek M.J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa-opioid receptors. Psychopharmacology (Berl) 179 3 (2005) 551-558